anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a model animal of bone diseases accompanied with fragility or breaking of bone tissues and to provide uses thereof and a method for producing the same.  <P>SOLUTION: The model animal of the diseases accompanied with fragility of the bone tissues expressing γGTP or GGT (γ-glutamyl transpeptidase) in the bone tissues is provided. The model animal readily reproduces osteoporosis symptoms in a short time. The fragility of the bone tissues can easily be traced by measuring lowering of bone density or a bone resorption marker in urine. The model animal is useful for screening a compound inhibiting the fragility of the bone tissues.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Group will undergo manual scar mobilization therapy. In this therapy, deep pressure on some point of the area of the scar will be given which will be perpendicular to the skin which will be followed by skin rolling. The manual therapy will include different techniques such as rolling, stroking, superficial rubbing, deep rubbing, breaking up, and pinching. The therapy will continue for 15 minutes.
Bipolar disorder is a chronic illness associated with significant personal and societal costs. Patients with bipolar disorder also experience more general medical comorbidities than the general population. Potential disparities exist in the receipt of medical and preventive care for individuals with serious mental illness compared to those without serious mental illness. The goal of this study is to pilot test an adapted version of the Wagner Chronic Care Model (CCM). Our target population will be all adult patients with a diagnosis of bipolar disorder (bipolar I, II, NOS) receiving care in the VA Pittsburgh Healthcare System. We plan on consenting and enrolling 60 patients, in which 30 will be randomized to receive the intervention, and 30 will receive usual care. Key components of the intervention include: 1) access to a Care Manager who will help patients make and keep appointments for general medical care by contacting patients on a regular basis; 2) a self-management program, which is education on adherence and self-management for patients by the Care Manager, including information on side-effects, bipolar disorder illness, and tips on communicating with general medical providers that will be provided during group sessions during the first 3 months of the study, and; 3) a registry that tracks patient progress maintained by the Care Manager. Both groups will receive practice guidelines for the treatment of medical conditions tailored to the needs of patients with bipolar disorder. Patients in the intervention arm will meet with the Care Manager after the baseline assessment, who will initially set up regular visits or contacts with the patients and work with them to connect with a primary care clinician. A Survey Coordinator will have patients complete a baseline assessment, and then a follow up assessment at 3 and 6 months later. Our primary outcome is changes in physical and mental health related quality of life. Secondary outcomes include changes in symptoms and functioning. Findings from this study will inform our long-term goal of implementing a larger scale version of the adapted CCM for veterans with bipolar disorder.
PURPOSE:To efficiently and easily obtain a polysaccharide to be suitably formulated in e.g. beverages of low turbidity with no deterioration over time, by adjusting the pH level of an aqueous solution of a water-soluble polysaccharide extracted from beans under an acidic state followed by heat treatment and then separating and removing the precipitate. CONSTITUTION:An aqueous solution of a water-soluble polysaccharide extracted from beans under an acidic state is adjusted to pH6 to <9 and then heat treated, and the precipitate ' is separated and removed. The beans to be used is soybean, and cotyledons of their seeds are used. The heat treatment is conducted by adding a reducing agent or oxidizing agent to the system; during or prior to the heat treatment, a treatment using a protease (e.g. pepsin, subtilisin, bromelain, papain) is carried out. A high-molecular flocculant may be added to the system in separating and removing the precipitate. The reducing agent is one selected from sodium hyposulfite, potassium hyposulfite and sodium or potassium bisulfite. The oxidizing agent is one selected from sodium hypochlorite, calcium hypochlorite, calcium hydroxyhypochlorite and hydrogen peroxide.
PURPOSE:A sustained release pharmaceutical, obtained by chemically bonding a medicine having functional groups to a chemically modified collagen, having high safety, capable of holding medicinal concentration in the tissue for a long period, useful as a pharmaceutical material, and having good prolonged action. CONSTITUTION:A sustained release pharmaceutical, obtained by chemically bonding a medicine having functional groups to a chemically modified collagen, particularly atherocollagen. The chemically modified collagen is most preferably succinylated atherocollagen prepared by converting the epsilon-amino groups into carboxyl groups. The medicine having the functional groups, e.g. pepleomycin, adriamycin or insulin which is a hormone, is then chemically bonded to succinimidated parent gelatin obtained by succinimide esterifying the above- mentioned compound. The resultant pharmaceutical is a sustained release pharmaceutical, prepared from collagen having good biocompatibility as a starting material and having good prolonged action.
UNLABELLED: People with prior lean mass loss had a ~ 10% higher risk of MOF and ~ 22-26% higher risk of hip fracture, and the results were similar in people on anti-osteoporosis medications. Loss of lean mass is associated with increased fracture risk. Patients should be encouraged to pursue strategies to prevent loss of lean mass.
BACKGROUND: Sarcopenia increases fracture risk. If the risk persists after starting osteoporosis medication, patients may need to be encouraged to pursue strategies to prevent loss of lean mass.
OBJECTIVE: To estimate the effects of loss in appendicular lean mass (ALM) or total body lean mass (TBLM) on subsequent fracture risk and effect modification with anti-osteoporosis medication use.
METHODS: We conducted a registry-based cohort study linked to population-based data. We identified individuals ≥ 40 years of age with two DXA assessments ≥ 1 year apart and minimum 0.5 years of observation. ALM and TBLM were estimated from weight, sex, and percent fat from DXA (R2 = 0.91 and 0.84 vs total body DXA, respectively). We report hazard ratios (HR) from Cox regression models estimating time to first incident major osteoporotic fracture (MOF) and hip fracture, adjusted for fracture risk; osteoporosis medication was included as an interaction term and used to stratify analyses.
RESULTS: We included 21,249 individuals (mean 67 [SD 10] years, 95% female, 37% on osteoporosis medication). The mean follow-up was 7 years (SD 4). A total of 1868 and 548 people had incident MOF and hip fracture, respectively. People with prior ALM loss (HR per SD 1.09, 95% CI 1.04-1.15) or TBLM loss (HR per SD 1.09, 95% CI 1.42-1.14) had a higher risk of MOF. Hip fracture risk was greater in people with prior ALM loss (HR per SD 1.22, 95% CI 1.12-1.33) and TBLM loss (HR per SD 1.26, 95% CI 1.16-1.38). There were no interactions with anti-osteoporosis medication use (all p > 0.3). When restricted to people on anti-osteoporosis medication, each SD in ALM or TBLM loss was associated with 8-9% increased MOF risk and 18-23% increased hip fracture risk.
CONCLUSIONS: Loss of lean mass is associated with increased fracture risk among individuals on anti-osteoporosis medication. Patients should be encouraged to pursue strategies to prevent sarcopenia.
Disclosed herein are compositions and methods for inducing (upregulating) expression of sulfotransferase in hair follicles (e.g., scalp). The addition of sulfotransferase facilitates metabolism of prodrugs that require sulfonation for activation, for example, minoxidil sulfate is an active metabolite of minoxidil. Methods of combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenic alopecia are described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in RXR-NR heterodimers. Additional methods and compositions include upregulating the sulphonation capacity of hair bearing skin, hair follicles and/or keratinocytes using topical solutions containing alkalizing agents or alkalizing agents used with penetration enhancers. In addition, compositions and methods for increasing or decreasing the rate of hair follicle growth by altering the intracellular pH are disclosed. Furthermore, a method of preparing a stable liposome-containing solution is described.
Fortified human milk is the first choice for preterm infants. Although individualized fortification is recommended, the optimal method for this population remains uncertain. We conducted a comparative study assessing the growth effects of adjusted (AF) and targeted fortification (TF) in extremely low birth weight (ELBW) infants. This single-center, randomized, controlled clinical trial was conducted at a tertiary neonatal unit in Spain. Eligible participants were premature infants with a birthweight of <1000 g exclusively fed with human milk. A total of 38 patients were enrolled, 15 of them randomized to AF group and 23 to TF group. AF was based on blood urea nitrogen (BUN) concentration and TF on human milk analysis. The primary outcome was weight gain velocity (g/kg/day). No significant differences were found in weight gain velocity at 28 days, at 36 weeks of postmenstrual age, at discharge, nor during the intervention. Protein intake was significantly higher in the AF group (5.02 g/kg/day vs. 4.48 g/kg/day, p = 0.001). No differences were found in the lipid, carbohydrate, and energy intake; in the weight z score change between the different time points; nor in the length and head circumference growth. Both AF and TF are comparable methods of fortification and provide the appropriate growth rate in ELBW infants.
PURPOSE: To obtain an amino acid compsn. effective in the cure of obesity, etc., and having a high net nitrogen utilization(NNU). CONSTITUTION: This nutritive compsn. contains an amino acid compsn., specified hydrocarbon and vitamin. The amino acid compsn. consists of isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine as essential amino acids and has at least 80% net nitrogen utilization.
Meaningful activity protocol during the day and Assisted Relaxation Therapy (ART) at night; includes 1) Sleep Hygiene Education; 2) Meaningful Activity Modules a) Physical Activity b) Cognitive Activity and c) Social engagement; 3) ART, a breath-based relaxation intervention that is coupled with a physical anchoring task. Participants will complete a daily sleep diary, use the activity modules daily as pre-determined times personalized to the participant, use the ART software when they get in bed to help with insomnia symptoms, and wear an actiwatch for a four-week period. Participants will have weekly to biweekly phone consultation with the research nurse.
PURPOSE:To provide the titled inhibitor containing a pyrazine derivative and effective also for the prevention of cancer metastasis. CONSTITUTION:The objective platelet coagulation inhibitor can be produced by using the compound of formula as an active component. It is useful as a preventive for diseases caused by the coagulation of platelet, i.e. thrombosis, metastasis of cancer, etc. Dose: 30-600mg daily, if necessary in 1-3 divided doses. It is administered preferably by oral administration, however, it can be administered also by intravenous injection. It is used in the form of tablet, powder, capsule, granule, etc., using a carrier or diluent such as calcium carbonate, calcium phosphate, starch, sucrose, lactose, talc, magnesium stearate, etc. It may be used as a liquid medicine such as suspension in oil, syrup, etc., or may be stabilized by including the compound with cyclodextrin.
Cell free nucleic acids from a test sample obtained from an individual are analyzed to identify possible fusion events. Cell free nucleic acids are sequenced and processed to generate fragments. Fragments are decomposed into kmers and the kmers are either analyzed de novo or compared to targeted nucleic acid sequences that are known to be associated with fusion gene pairs of interest. Thus, kmers that may have originated from a fusion event can be identified. These kmers are consolidated to generate gene ranges from various genes that match sequences in the fragment. A candidate fusion event can be called given the spanning of one or more gene ranges across the fragment.
A patient health management system includes a personal computing system having a computer readable memory storing computer executable code. The system further includes a microprocessor configured to execute the computer executable code and compare stored medication library data with image data associated with a digital image of a medication captured by a digital imaging device of the personal computing system. The microprocessor is further configured to link profile data for a patient-user of the personal computing system with identification data for the medication and output an administration confirmation request based on the linked data. The administration confirmation request may include a wireless signal transmitted to a remote computing system to enable a remote computer or a health services provider to confirm that planned self-administration of medication by a patient is correct. Pharmacy errors, potential medication interaction, and other conflicts may be proactively addressed, and the patient may be alerted via signals sent to a personal communication device. Action conditions other than potential conflicts may also be detected and addressed, such as suitability for patient participation in clinical research studies.
The subjects enrolled in this protocol will dedicate 33 days of home-based measurement and two days for in-clinic measurements. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed using the thenar of the right hand of the subject.
Allergic reactions to any of the ingredients can occur, ranging from mild skin irritation to severe anaphylaxis in rare cases. Allergic sensitization has been reported following both oral and parenteral administration of folate.

  
Niacinamide, a form of niacin, may cause flushing, itching, and tingling sensations in some individuals, particularly when taken in higher doses. This effect is usually harmless but can be uncomfortable. Some individuals may experience gastrointestinal symptoms such as nausea, bloating, or diarrhea, especially when consuming higher doses of certain ingredients like garlic and black pepper. Certain ingredients in the product, such as garlic and black pepper, may interact with medications. Garlic may potentiate the effects of anticoagulant medications, while black pepper may affect the metabolism of certain drugs.
As the Coronavirus Disease 2019 (COVID-19) pandemic continues, there is a growing concern regarding the relationship between viral infections and neuropathic pain. Chronic neuropathic pain resulting from virus-induced neural dysfunction has emerged as a significant issue currently faced. However, the molecular mechanisms underlying this phenomenon remain unclear, and clinical treatment outcomes are often suboptimal. Therefore, delving into the relationship between viral infections and neuropathic pain, exploring the pathophysiological characteristics and molecular mechanisms of different viral pain models, can contribute to the discovery of potential therapeutic targets and methods, thereby enhancing pain relief and improving the quality of life for patients. This review focuses on HIV-related neuropathic pain (HNP), postherpetic neuralgia (PHN), and neuropathic pain caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections, examining rodent models and relevant cellular molecular pathways. Through elucidating the connection between viral infections and neuropathic pain, it aims to delineate the current limitations and challenges faced by treatments, thereby providing insights and directions for future clinical practice and research.
MS prevalence increases after the onset of menopause, because of estrogen deficiency. It is still not clear if menopause itself increases the risk of cardiovascular diseases in al women or only in those that develop MS. Many MS patients that show slight modification in cardiovascular and metabolic parameters are not generally pharmacologically treated since diabetes or alteration in the lipid profile are not evidenced. In this respect it is of importance to develop new therapeutic strategies to prevent and treat MS. Genistein (4,5,7-trihydroxyisoflavone), shown a potentially preventive role on the cardiovascular apparatus in post-menopausal women, may be termed as selective ER modulator (SERM), since it reveals both ER-alpha full agonist and ER-beta partial agonist activity.

The investigators studied whether genistein may represent an efficacious and safe alternative for reducing vascular risk in postmenopausal women with metabolic syndrome. The clinical study was a randomized, double-blind, placebo-controlled study involving 150 patients with metabolic syndrome. After a 4-week stabilization on a standard fat-reduced diet, participants were randomly assigned to receive either phytoestrogen genistein (54 mg/day) or placebo for 6 months. At baseline and following treatment fasting plasma glucose, insulin, insulin resistance (HOMA-IR), lipid concentrations, plasma total homocysteine, leptin, adiponectin and visfatin were measured. Bioimpedentiometric and nutritional analysis, as well as a safety assessment of the endometrium and vagina were also performed.
Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
All ERCP was performed with the patient in the prone position using a SBE (SIF-H290S; Olympus Corp., Japan) under CO2 insufflation and conscious sedation. A soft transparent hood (D-201-11804; Olympus Corp., Japan) was used in all cases. The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
Patients meeting eligibility criteria(mutation +ve and having EEG spikes), will be admitted to the Pediatric Clinical Research Unit at Johns Hopkins Hospital and will have pharmacokinetics of DM determined to establish that they are rapid metabolizers of the drug. The baseline studies on initial admission include neurological, neuropsychology,EEG, gastroenterology, Occupational and Physical therapy evaluations. If the subject is a rapid metabolizer they will be randomized to one of the three drug doses. They are contacted by telephone, weekly in the first month, and monthly thereafter. They will be examined by a neurologist at 2 weeks,1 month, and 3 months during the drug trial. At each of these visits they will also be monitored for changes in complete blood count (CBC), electrolytes, and EKG. At the end of the 6 month drug trial the patients will be readmitted to Johns Hopkins Hospital when all baseline studies are repeated. Cost of travel, hospitalization and interim tests are free to participants.
Gonadotropin-releasing hormone (GnRH) analogs are the mainstay of treatment for central precocious puberty (CPP) since 1985. The relatively short time period elapsed since the introduction of this therapy has not allowed until now to carry out exhaustive studies on the long-term evolution of treated patients. This project will analyze the long-term outcomes of patients with CPP treated or not with GnRHas on adult height, body mass index, body composition, metabolic disorders, bone mineralization, gonadal function, and fertility in comparison to a control group. Overweight before puberty is associated to earlier menarche, and conversely, earlier menarche predispose to adult obesity and metabolic disorders. Nevertheless, it is unclear if adult adiposity is a direct consequence of early puberty or if early puberty is a marker of a predisposition to excess adiposity from prepuberty through adult life. Recent data in rodent models support the hypothesis that early nutritional status determines a risk for both childhood and adult obesity and influences pubertal timing. In girls, early weight gain in childhood has been associated with early menarche. Pattern of growth rather than absolute level of fatness seem to be of most importance. So the first aim of this study is to compare the outcomes of CCP patients with or without an early adiposity rebound and to demonstrate that adiposity rebound more than CPP per se or the GnRHas therapy affect the outcomes. Moreover, recent genome-wide association studies have identified obesity-related gene variants associated with earlier age at menarche. The investigators hypothesized that there might be a genetic basis underlying the early programming of both childhood and adulthood adiposity and puberty timing. The investigators thus aim to determine if those obesity-related gene variants associated with an early but not precocious menarche could also be found in CPP, especially in girls with an early adiposity rebound and if their presence may affect adult health.
The hepatitis B virus (HBV) capsid is made up of a single species of protein called the core antigen (HBcAg) which self-assembles into particles. The particles are highly immunogenic and are able to present heterologous epitopes to the immune system when the epitopes are inserted into a surface-exposed region of the particles called the “el loop”. The structural building blocks of the particles are tightly associated dimers of HBcAg in which the adjacent el loops are closely juxtaposed. It is proposed that sequences inserted into the el loop are conformationally restrained in the assembled particles when presented in monomeric core protein. The invention seeks to solve this problem by covalently linking core proteins as tandem copies, e.g., as dimers, so that insertions can be made independently in each copy. This is particularly useful for insertion of large sequences into the el loop because it allows such sequences to be inserted into just one copy of the core protein per tandem repeat, thereby reducing potential conformational clashes in assembly. Alternatively, a different sequence may be inserted into each el loop of a tandem repeat, thus increasing the flexibility of HBcAg particles as an epitope delivery system.